Literature DB >> 2833915

Purification of 120,000 dalton envelope glycoprotein from culture fluids of human immunodeficiency virus (HIV)-infected H9 cells.

S W Pyle1, J W Bess, W G Robey, P J Fischinger, R V Gilden, L O Arthur.   

Abstract

The outer envelope glycoprotein, gp120, has been purified from large volumes (greater than 100 liters) of HTLV-IIIB-infected H9 cell culture fluids using immunoaffinity chromatography resins prepared from immunoglobulins of AIDS patients plasma. By using a single-step immunoaffinity purification, between 7 and 28 micrograms of gp120 was recovered from each liter of culture fluid which represented between 60 and 95% of the total envelope glycoprotein present in the fluid. Envelope glycoprotein in culture media was concentrated more than 10,000 times over the starting material. The water-soluble gp120, containing trace contaminating proteins, was purified to apparent homogeneity by preparative polyacrylamide gel electrophoresis (PAGE). Envelope glycoprotein purified from culture fluids was immunogenic in laboratory animals in both native and PAGE-purified forms and was reactive with AIDS patient sera in immunoassays.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2833915     DOI: 10.1089/aid.1987.3.387

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA.

Authors:  R J Gorelick; S M Nigida; J W Bess; L O Arthur; L E Henderson; A Rein
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

2.  Expression of the human immunodeficiency virus envelope glycoprotein is restricted to basolateral surfaces of polarized epithelial cells.

Authors:  R J Owens; R W Compans
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Elena Chertova; Julian W Bess; Bruce J Crise; Raymond C Sowder II; Terra M Schaden; Joanne M Hilburn; James A Hoxie; Raoul E Benveniste; Jeffrey D Lifson; Louis E Henderson; Larry O Arthur
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF.

Authors:  S W Pyle; G C Dubois; W G Robey; J W Bess; P J Fischinger; L O Arthur
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

5.  Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120.

Authors:  I Sekigawa; K Koshino; T Hishikawa; H Kaneko; Y Takasaki; H Hashimoto; S Hirose; Y Inagaki; N Yamamoto
Journal:  J Clin Immunol       Date:  1995-11       Impact factor: 8.317

6.  Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.

Authors:  N Sullivan; Y Sun; J Binley; J Lee; C F Barbas; P W Parren; D R Burton; J Sodroski
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

7.  Enzyme-linked immunoassay for human immunodeficiency virus type 1 envelope glycoprotein 120.

Authors:  M Gilbert; J Kirihara; J Mills
Journal:  J Clin Microbiol       Date:  1991-01       Impact factor: 5.948

8.  HIV Apheresis Tags (HIVAT) Aided Elimination of Viremia.

Authors:  Marek Malecki; Bianka Saetre
Journal:  Mol Cell Ther       Date:  2018-06-21

9.  HIV gp120 binds to mannose receptor on vaginal epithelial cells and induces production of matrix metalloproteinases.

Authors:  Sashaina E Fanibunda; Deepak N Modi; Jyotsna S Gokral; Atmaram H Bandivdekar
Journal:  PLoS One       Date:  2011-11-22       Impact factor: 3.240

10.  Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis.

Authors:  N K Banda; J Bernier; D K Kurahara; R Kurrle; N Haigwood; R P Sekaly; T H Finkel
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.